uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences. (osteoporos)
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences. (Akut- och internmedicin)
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences. (Ortopedi)
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences.
Show others and affiliations
2003 (English)In: Journal of Hypertension, ISSN 0263-6352, Vol. 21, no 3, 621-4 p.Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE: Hypertension is associated with a number of adverse morphologic and functional changes in the cardiovascular system, including left ventricular (LV) hypertrophy. Studies have demonstrated that bradykinin, through the B2 bradykinin receptor (B2BKR), mediates important cardiovascular effects that may protect against LV hypertrophy. Recently, a +9/-9 exon 1 polymorphism of the B2BKR was shown to be strongly associated with LV growth response among normotensive males undergoing physical training. We aimed to clarify whether the processes found in exercise-induced LV growth in normotensive people also occur in pathological LV hypertrophy. DESIGN AND METHODS: We determined the B2BKR genotype of 90 patients with essential hypertension and echocardiographically diagnosed LV hypertrophy, included in a double-blind study to receive treatment for 48 weeks with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan or the beta1-adrenoceptor antagonist atenolol. RESULTS: B2BKR +9/+9 genotypes responded poorly in LV mass regression, independent of blood pressure reduction or treatment, as compared to the other genotypes (adjusted mean change in LV mass index = -10.0 +/- 4.6 versus -21.6 +/- 2.2 g/m2, P = 0.03). CONCLUSIONS: Our results suggest an impact of the B2BKR polymorphism on LV mass regression during antihypertensive treatment.

Place, publisher, year, edition, pages
2003. Vol. 21, no 3, 621-4 p.
Keyword [en]
Adrenergic beta-Antagonists/therapeutic use, Angiotensin II Type 1 Receptor Blockers, Antihypertensive Agents/*therapeutic use, Atenolol/*therapeutic use, Biphenyl Compounds/*therapeutic use, Double-Blind Method, Female, Genotype, Humans, Hypertension/*drug therapy/*genetics/pathology, Hypertrophy; Left Ventricular/*drug therapy/*genetics/pathology, Male, Middle Aged, Organ Size/drug effects, Polymorphism; Genetic, Receptor; Bradykinin B2/*genetics, Research Support; Non-U.S. Gov't, Sweden, Tetrazoles/*therapeutic use
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-73227DOI: 10.1097/01.hjh.0000052474.40108.c9PubMedID: 12640257OAI: oai:DiVA.org:uu-73227DiVA: diva2:101138
Available from: 2007-04-20 Created: 2007-04-20 Last updated: 2009-10-22Bibliographically approved
In thesis
1. Pharmacogenomics of Antihypertensive Treatment & Clinical Pharmacological Studies of Digoxin Treatment
Open this publication in new window or tab >>Pharmacogenomics of Antihypertensive Treatment & Clinical Pharmacological Studies of Digoxin Treatment
2005 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

In Part I we found that the CYP2C9 genotype appears to influence the diastolic blood pressure response to the angiotensin II-receptor antagonist irbesartan in patients with hypertension and left ventricular hypertrophy. Those with the *1/*2 genotype (slower metabolism) responded better than those with the *1/*1 genotype (normal metabolism), likely due to a slower elimination of the drug. We further found that a +9/-9 exon 1 polymorphism of the B2 bradykinin receptor gene – shown to affect mRNA expression - appears to influence the regression of left ventricular mass during therapy with irbesartan or the beta-blocker atenolol in the same patients. Subjects with the -9/-9 genotype (higher mRNA expression) had a greater regression than carriers of the +9 allele.

In Part II we found that women on digoxin therapeutic drug monitoring have higher serum digoxin concentrations (SDCs) as compared to men (1.54±0.04 [nmol/L±SE] vs 1.20±0.05 [nmol/L±SE], p<0.001), which could be of importance since an SDC >1.4 nmol/L has been associated with increased mortality. We further found that coadministration of P-glycoprotein inhibitors with digoxin was common (47%) among the same patients, and that the SDC increased in a stepwise fashion with the number of P-glycoprotein inhibitors (20-60%). Lastly, we found that patients admitted to Swedish coronary care units with atrial fibrillation without heart failure and who had been given digoxin had a higher 1-year mortality than those not given digoxin (RR 1.44 [95% CI 1.29-1.60], adjustment made for potential confounders).

In conclusion, Part I represents a further step in the pharmacogenomic prospect of tailoring antihypertensive therapy. Part II indicates that heightened attention to the digoxin-dose is warranted in women, that there is a need for awareness about P-glycoprotein interactions with digoxin, and that long-term therapy with digoxin is an independent risk factor for death among patients with atrial fibrillation without heart failure.

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2005. 107 p.
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, ISSN 1651-6206 ; 36
Molecular medicine, pharmacogenomics, irbesartan, atenolol, hypertension, digoxin, RIKS-HIA, atrial fibrillation, heart failure, Molekylärmedicin
National Category
Medical Genetics
urn:nbn:se:uu:diva-5782 (URN)91-554-6241-3 (ISBN)
Public defence
2005-05-25, Enghoffsalen, Entrance 50, Uppsala University Hospital, Uppsala, 13:15 (English)
Available from: 2005-05-04 Created: 2005-05-04 Last updated: 2009-08-14Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=12640257&dopt=Citation

Search in DiVA

By author/editor
Hallberg, PärLind, LarsMichaëlsson, Karl
By organisation
Department of Medical SciencesDepartment of Surgical Sciences
In the same journal
Journal of Hypertension
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 240 hits
ReferencesLink to record
Permanent link

Direct link